Breaking Corporate Events, Analysed in Real Time

Aurobindo Pharma Secures USFDA Approval for First MDI Product in US$301M Market

Aurobindo Pharma has received final USFDA approval for Beclomethasone Dipropionate HFA Inhalation Aerosol, marking its entry into the metered-dose inhaler (MDI) segment. The product targets a US market valued at approximately US$301 million and will be manufactured in North Carolina.

Aurobindo Pharma Subsidiary Lannett Launches First US Inhalation Product in $908M Market

Aurobindo Pharma's subsidiary, Lannett Company LLC, has commercialised a generic version of Advair Diskus in the United States. This represents the company's entry into the complex US inhalation market, targeting a therapeutic area valued at nearly $1 billion.